key: cord-0782447-ttwcwzf1
authors: Biering, Scott B.; Van Dis, Erik; Wehri, Eddie; Yamashiro, Livia H.; Nguyenla, Xammy; Dugast-Darzacq, Claire; Graham, Thomas G.W.; Stroumza, Julien R.; Golovkine, Guillaume R.; Roberts, Allison W.; Fines, Daniel M.; Spradlin, Jessica N.; Ward, Carl C.; Bajaj, Teena; Dovala, Dustin; Gahmen, Ursula Schulze; Bajaj, Ruchika; Fox, Douglas M.; Ott, Melanie; Murthy, Niren; Nomura, Daniel K.; Schaletzky, Julia; Stanley, Sarah A.
title: Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2
date: 2020-12-30
journal: bioRxiv
DOI: 10.1101/2020.12.30.424862
sha: e32b2410997beb23f92cb1807d3339fd0b706076
doc_id: 782447
cord_uid: ttwcwzf1

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has emerged as a major global health threat. The COVID-19 pandemic has resulted in over 80 million cases and 1.7 million deaths to date while the number of cases continues to rise. With limited therapeutic options, the identification of safe and effective therapeutics is urgently needed. The repurposing of known clinical compounds holds the potential for rapid identification of drugs effective against SARS-CoV-2. Here we utilized a library of FDA-approved and well-studied preclinical and clinical compounds to screen for antivirals against SARS-CoV-2 in human pulmonary epithelial cells. We identified 13 compounds that exhibit potent antiviral activity across multiple orthogonal assays. Hits include known antivirals, compounds with anti-inflammatory activity, and compounds targeting host pathways such as kinases and proteases critical for SARS-CoV-2 replication. We identified seven compounds not previously reported to have activity against SARS-CoV-2, including B02, a human RAD51 inhibitor. We further demonstrated that B02 exhibits synergy with remdesivir, the only antiviral approved by the FDA to treat COVID-19, highlighting the potential for combination therapy. Taken together, our comparative compound screening strategy highlights the potential of drug repurposing screens to identify novel starting points for development of effective antiviral mono- or combination therapies to treat COVID-19.

Zoonotic viruses pose a great public health challenge due to the unpredictable nature of an outbreak, the potential to impact an immune-naïve population, and a lack of therapeutic options (1, 2). Coronavirus disease 2019 is caused by the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the Coronaviridae family within the Betacoronavirus genus (3) (4) (5) . The Betacoronavirus genus contains several seasonal human pathogens that cause mild disease, as well as the recently emerged severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) (4) . SARS-CoV-2, SARS-CoV, and MERS-CoV cause severe disease in humans. The increased magnitude of the current pandemic relative to SARS-CoV and MERS-CoV may be explained by increased human-human transmissibility from frequent asymptomatic shedding of this virus (6) (7) (8) (9) . Severe cases of COVID-19 are associated with acute respiratory distress syndrome (ARDS) triggered by an inflammatory response resulting in tissue damage and fluid accumulation in the lungs (10) (11) (12) . Currently there are limited options to treat patients suffering from severe COVID-19. The sole FDA-approved antiviral compound for COVID-19 treatment is remdesivir, but clinical efficacy is modest and no conclusive effect on patient mortality has been found (13) (14) (15) (16) . Although remdesivir exhibits strong in vitro efficacy against SARS-CoV-2 infection, its low exposure in target lung tissue, dose-limiting kidney and liver toxicity, and the need for intravenous administration make early and effective clinical treatment difficult (17) (18) (19) (20) . Consequently, the rapid discovery and development of additional therapeutics is vital.

Repurposing well-studied preclinical, clinical, and approved compounds holds the greatest potential to swiftly move a drug candidate from the bench to the clinic. An FDA-approved compound library (TargetMol L4200) and a bioactive compound library (TargetMol L4000) are two collections of well-studied compounds, many of which already possess extensive human safety data. Here, we screened both libraries to identify compounds that inhibit SARS-CoV-2 replication in host cells. We report the identification of 13 compounds effective against SARS-CoV-2, 7 of which are previously unreported. Of note, a host-directed compound, the cyclindependent kinase (CDK) inhibitor dinaciclib, was determined to be more potent than remdesivir in limiting viral replication in human lung epithelial cells. Additional hit compounds include: i) known antivirals predicted to target SARS-CoV-2 viral factors directly; ii) host protein kinase and protease inhibitors; and iii) and anti-inflammatory agents. Further, we identify antiviral synergy between remdesivir and the RAD51 inhibitor B02, opening the possibility of clinical combination therapy. Taken together, our results identify several novel starting points for COVID-19 drug development which hold the potential to alleviate the current global pandemic.

To design a screen for identification of SARS-CoV-2 antiviral compounds, we first tested a panel of 16 cell lines to identify cells capable of sustaining robust SARS-CoV-2 replication. These cell lines included human pulmonary epithelial and endothelial cells, keratinocytes, hepatocytes, and primate cells, among others (Figure 1 and Figure S1 ). Multi-step growth curves of SARS-CoV-2 in each of these cell lines revealed a range of permissiveness to viral infection (summarized in Table 1 ). We found distinct cell infection patterns including highly permissive for viral replication ( Figure 1A-D) with and without significant cytopathic effect (CPE) ( Table 1) , mildly permissive with no CPE ( Figure S1 , Table 1 ), as well as non-permissive defined by lack of detectable infectious virus measured by a median tissue culture infectious dose assay (TCID50) ( Figure   S1 , Table 1 ). We selected the human pulmonary epithelial cell line Calu-3 and the African Green Monkey kidney cell line Vero-E6 for conducting the primary screens, as these cell types supported high levels of infection with dramatic CPE, ideal features for drug screening ( Figure  1A and 1B). We further reasoned that selection of two distinct cell lines would control for cellspecific effects of a given compound.

A cytopathic effect-based screening platform to identify SARS-CoV-2 antiviral compounds from the FDA-approved and bioactive compound libraries.

We screened a library of 1,200 FDA approved compounds (FDA-approved library) and a library of 2,834 pre-clinical compounds and 1,336 compounds with human clinical data (bioactive library, Figure S2A) . For the primary screen, we developed a CPE-based screening assay (CellTiter-Glo, CTG) which uses ATP released from viable cells to drive a luciferase reporter (RLU). This assay identifies drugs that are potent enough to inhibit SARS-CoV-2-mediated cell death, thus selecting for compounds whose antiviral effects are present over several viral lifecycles. Cells are treated with compound immediately prior to infection with SARS-CoV-2 and incubated until complete CPE is observed in infected vehicle treated wells, at which time cell viability is determined using the CTG assay (Figure 2A) . We used both Calu-3 and Vero-E6 cells to identify possible cell type dependent effects of each compound. We observed significant separation in signal between infected and uninfected wells in Vero-E6 cells at day demonstrating that the assay was suitable for high-throughput screening. Remdesivir served as a positive control in this assay, with EC50 values of 0.7-3µM ( Figure S2B, S2C) . For primary screens, three identical 384-well daughter plates were generated at a final compound concentration of 40 µM. Two plates served as technical replicates that were infected with SARS-CoV-2, while the third functioned as an uninfected cell cytotoxicity control (Figure 2A) .

To enable comparative analysis, we ran two parallel screens using the FDA-approved compound library on both Vero-E6 and Calu-3 cells. These screens revealed numerous compounds that significantly inhibited CPE in both cell types without causing significant cytotoxicity in uninfected cells (Figure 2D-F) . Intriguingly, although some compounds displayed overlapping antiviral activity in both cell lines, the majority displayed cell specific antiviral activity ( Figure 2F) . These observations could be explained by species-specific or cell type-specific mechanisms of action of a given compound, or by differences in viral replication between the two cell types. Because we observed cell type-specific effects of compounds, we proceeded to screen the remaining compounds from the bioactive library using Calu-3 human pulmonary epithelial cells only, which is more physiologically relevant to human infection. Selecting a hit signal cutoff of >1.5 and >2.1 standard deviations from the library mean for the FDA approved and bioactive library, respectively, our screens identified a total of 140 unconfirmed compounds that significantly inhibit SARS-CoV-2-mediated CPE ( Figure 2E and 2F). Best hits were selected for dose response assays based both on these primary screen data and an assessment of their suitability as potential COVID-19 therapeutics and prioritized for follow-up validation experiments using an experimental pipeline designed to narrow down our list of candidates to only the most promising compounds.

Leveraging the fact that compounds in the FDA-approved and bioactive libraries are well characterized with many drug targets previously defined, we conducted a gene set enrichment analysis (GSEA) of our candidate compounds to shed light on host-pathways important for SARS-CoV-2 replication. We found significant enrichment of compounds targeting host cyclindependent kinases (CDK1, CDK2, and CDK9), GSK-3β, C-RAF, and JNK1-3, suggesting that ubiquitous host pathways such as cell-cycle progression, MAPK-signaling, as well as GSK-3signaling are critical for SARS-CoV-2 infection. This agrees with a previously published analysis based on phosphoproteomics of cells infected with SARS-CoV-2 (21) ( Figure 2G) . Thus, our screen suggests these cellular pathways may contain druggable targets for inhibition SARS-CoV-2 infection of human lung cells.

To validate the in vitro potency of drug candidates revealed in our screen, we determined the half-maximal effective concentrations (EC50) of each compound by conducting dose response curves in the cell line in which compounds were identified using our optimized CTG system as a readout ( Figure S2C ). Confirmation rates in the secondary dose response screen were 72% for the Calu-3 and 67% for the Vero-E6 screen, highlighting assay reproducibility and suitability for hit identification (Figure 3, Figure S3 ). Our results identified 17 compounds with EC50 values below 10 µM, including 6 below 5 µM, without significant cytotoxicity. Data for the most potent compounds in Calu-3 cells are shown in Figure 3 and Figure S3 . From this list of candidates, the top 12 compounds were selected for down-stream validation (Figure 3 ). Hits were classified into four distinct categories based upon their proposed mechanism of action, including (1) protein kinase and protease inhibitors, (2) anti-inflammatory compounds, (3) direct-acting antivirals, and (4) other host factor-targeting compounds. This set of hits contained compounds with previously reported SARS-CoV-2 antiviral activity (dinaciclib, GC376 sodium, cyclosporin A, and camostat mesylate) and seven compounds that have not previously been reported to have anti-SARS-CoV-2 activity (Table 2) (21-24). These unreported compounds include the CDK inhibitor AZD5438, the AKT inhibitor SC66, the VEGFR inhibitor BFH772, the NADPH oxidase inhibitor GKT137831, the RAD51 inhibitor B02, the steroid budesonide, and the antiinflammatory compound cantharidin.

As our CPE-based screening assay measures SARS-CoV-2 induced cell death indirectly through quantification of ATP from viable cells, this assay does not directly test for antiviral activity of a given compound. To confirm the SARS-CoV-2 antiviral activity of our top 12 compound candidates, we tested their capacity to antagonize viral infection of Calu-3 cells through TCID50 and qRT-PCR assays. Also included was the PIKfyve kinase inhibitor apilimod mesylate, identified in Riva et al. 2020 (22) . We found all tested candidates possessed significant antiviral activity with viral titer reductions of infectious virus and genome equivalents ranging from 1-4 logs compared to vehicle control treated cells ( Figure 4A-H) . Intriguingly, we found that the CDK inhibitor dinaciclib (EC50 0.13 µM) was more potent in our assays than remdesivir (EC50 2.45 µM) in limiting viral titers in Calu-3 cells as measured by TCID50 and qRT-PCR (Table 2) .

Since the antiviral activity of compounds in vitro may be cell-type specific, we tested the capacity of a smaller subset of our candidates (dinaciclib, camostat mesylate, BFH772, budesonide, GC376 sodium, apilimod mesylate, GKT137831, B02, and cyclosporin A) to antagonize virus infection across multiple cell types. Compounds were selected based on their lack of cytotoxicity across all cell lines (data not shown). We utilized an immunofluorescence confocal microscopy assay (IFA) to measure the capacity of these 8 compounds to inhibit SARS-CoV-2 replication in 3 diverse cell lines including Huh-7 (human hepatocytes), human pulmonary microvascular endothelial cells stably expressing the SARS-CoV-2 receptor human ACE2 (HPMEC/hACE2) (25) , and Vero-E6 cells (Table 1) . Cells are treated with compound immediately prior to infection with SARS-CoV-2 and incubated for 24-48 hours. We then stained for the SARS-CoV-2 nucleoprotein (N) and calculated antiviral activity as % decrease in cell infection compared to vehicle treated infected cells. We found that the antiviral activity of GC376 sodium and apilimod mesylate were conserved across these cell lines ( Figure 5A -B) while all other tested drugs exhibited cell type specific activity ( Figure 5C -I). GC376 sodium has been suggested to inhibit SARS-CoV-2 M protease (Mpro) (26) , which may explain its efficacy across cell lines.

To shed light on mechanisms of action, we tested whether our top compounds inhibit SARS-CoV-2 Mpro or papain-like protease (PLpro). Conducting in-house developed SARS-CoV-2 protease cleavage assays, we identified disulfiram as a potent PLpro inhibitor and both disulfiram and GC376 sodium as Mpro inhibitors, confirming previous observations (26) (27) (28) ( Figure S4) . Notably, high concentrations of disulfiram exhibited antiviral activity in Calu-3 cells with 3 log reductions of viral titer and genome equivalents in TCID50 and qRT-PCR assays compared to vehicle control treated cells, potentially explaining its antiviral mechanism of action ( Table 2 ). In summary, these data highlight the benefit of a target-agnostic approach to expose previously unknown mechanisms of identified antivirals, as well as the importance of testing and validation across multiple cell lines for anti-viral screening.

Combination therapy is a highly desirable approach for treating SARS-CoV-2 infections (29) .

Because our screen revealed only a single compound (dinaciclib) possessing greater antiviral activity than remdesivir when used as a monotherapy, we asked if our compound candidates possess synergistic antiviral activity when used in combination with remdesivir. To assess this, we conducted a CPE inhibition assay using 10 µM of B02 in the presence or absence of an EC15 of remdesivir (2 µM, Figure S2B -C) in Vero-E6 cells. Interestingly, the RAD51 inhibitor B02 exhibited potent synergistic activity with remdesivir ( Figure 6A ). We confirmed these results in Calu-3 cells by conducting a dose response of remdesivir in the presence or absence of 10 µM B02 and observed a >10-fold shift in the EC50 of remdesivir. from 1 µM to <0.08 µM ( Figure 6B ). Taken together, these observations suggest that in addition to providing new starting points for therapeutic development, B02 may be pursued as a combination therapy with remdesivir to develop treatments for COVID-19 patients.

In this study, we screened a library of FDA-approved, clinical, and pre-clinical compounds for antiviral activity against SARS-CoV-2, with the goal of rapidly repurposing drug candidates for clinical use during the COVID-19 pandemic. We identified multiple cell lines that were permissive to SARS-CoV-2 infection and conducted primary screens using virus-induced CPE as a functional readout in two highly permissive but divergent cell types (Vero-E6 and Calu-3).

We identified many compounds displaying varying degrees of antiviral activity across distinct cell lines including Vero-E6, Calu-3, HPMEC/hACE2, and Huh-7. These cell-type dependent phenotypes suggest significant cell type-dependency of compound efficacy in vitro. We further validated a subset of candidates to define EC50 values, confirmed antiviral activity in orthogonal assays, probed mechanism of action, and demonstrated antiviral synergy of one compound with remdesivir. While our investigation successfully identified compounds published previously, we also identified 7 potent compounds that to our knowledge have not been previously reported.

They include the RAD51 inhibitor B02, the CDK inhibitor AZD5438, the AKT inhibitor SC66, the VEGFR inhibitor BFH772, the NADPH oxidase inhibitor GKT137831, the steroid budesonide, and the anti-inflammatory compound cantharidin. Further, B02 was found to synergize with remdesivir, shifting the apparent EC50 of remdesivir more than 10-fold. Together, our results present new possibilities for FDA-approved and other well-validated candidate drugs to be repurposed for remdesivir combination therapy.

The cell-type dependent antiviral efficacy of many of our drug candidates within this screen indicates a strong selection bias is introduced by the selection of cell type used in the screen.

The biological reason for this is likely due to distinct cell-type expression patterns of host-factors essential for SARS-CoV-2 replication or differential drug metabolism. For example, SARS-CoV-2 requires proteolytic cleavage of the Spike (S) glycoprotein by a host protease once it binds to the ACE2 receptor (30) (31) (32) . This cleavage can be performed by multiple host proteases including TMPRSS2 and cathepsin L, whose expression levels vary significantly between different cell lines (30, 33, 34) . Vero-E6 cells do not express TMPRSS2, meaning any drug targeting TMPRSS2, or the interaction between S and TMPRSS2, would not emerge as a hit in such a cell line (32) . Indeed the drug candidate camostat mesylate, a TMRPSS2 inhibitor currently in clinical trials (35) inhibited SARS-CoV-2 in Calu-3 but not Vero-E6 cells ( Figure 5 ).

Conversely, GC376 sodium, a previously characterized SARS-CoV-2 protease inhibitor, maintains its antiviral activity across multiple cell lines in our study, suggesting that compounds targeting viral factors may be expected to show activity across different tissues, although the extent of activity can differ based on prodrug metabolism, as previously observed with remdesivir (26, 27, 36) . Pharmacokinetics and dynamics must be taken into account for each compound and may be influenced by the metabolic state of distinct cell lines or tissue within infected humans. Our comparative cell line investigation of antiviral compounds highlights cell line selection as a critical step when conducting SARS-CoV-2 drug screens and may explain disparate data obtained in different studies (21) (22) (23) (37) (38) (39) (40) (41) (42) .

Defining the mechanisms of action of antiviral compounds is critical to determine how a compound may be modified to improve antiviral efficacy and to suggest the compounds' pharmacokinetic and pharmacodynamic limitations. An advantage of screening libraries of well characterized compounds is that the molecular targets of many compounds are already determined. GSEA analysis of our top antiviral candidates revealed a set of enriched host and viral targets. Our candidate compounds possess distinct mechanisms of action including host kinase and protease inhibition, anti-inflammatory activity, and direct antiviral efficacy targeting virus factors. Our results also implicate host-pathways that are critical for SARS-CoV-2 viral replication including regulation of the cell cycle through modulating CDKs, regulating MAPK signaling through modulation of c-JUN N-terminal kinases (JNK), and modulation of glycogen synthase kinase 3 (GSK-3). Our screening results are consistent with other reports that these diverse cellular pathways are likely to be critical for the SARS-CoV-2 lifecycle (21, (43) (44) (45) (46) .

These observations call for further mechanistic investigation of the dependency of SARS-CoV-2 on these various host pathways and highlight the potential of repurposing other drugs not studied here that target these pathways.

Though our study identified many distinct antiviral candidates, only dinaciclib exceeded the in vitro potency of remdesivir, suggesting that few, if any, "magic bullet" compounds exist in the library of FDA-approved and clinical/preclinical compounds. This is not unexpected for a repurposing approach, and therefore, combination therapy may be the best strategy to achieve high efficacy rapidly (29) . Here, we identify the RAD51 inhibitor B02 as highly synergistic with remdesivir in both Vero-E6 and Calu-3 cells. The mechanism of action of this antiviral synergy is currently unclear and an active area of investigation. As RAD51 is known to play a role in DNA repair and strand exchange via interactions with CDK1 during the cell cycle, its mechanism of action may be connected to the dependency of SARS-CoV-2 on cell-cycle arrest during infection and repurposing of host machinery for viral replication (21, (47) (48) (49) (50) . Because remdesivir functions as a nucleoside analog that inhibits the function of the SARS-CoV-2 RNA-dependent RNA Polymerase (RdRP) during replication (51, 52) , the antiviral activity of remdesivir may be enhanced when the virus is unable to modulate the cell cycle in such a way that promotes optimal viral RNA replication (50) . Alternatively, RAD51 may directly promote SARS-CoV-2 replication as a component of the viral replication complex, as it is also reported to localize to the membranous replication complex of hepatitis c virus (HCV) where it interacts with the HCV nonstructural protein 3 (53) . RAD51 may function comparably for SARS-CoV-2 and thus B02 may interfere with SARS-CoV-2 replication machinery in a manner that enhances the activity of remdesivir. This is further supported by the observation that B02 possesses antiviral activity in the absence of remdesivir suggesting either that RAD51 plays a direct role in promoting viral replication or that B02 has activity against other targets. We have previously observed antiviral synergy against SARS-CoV-2 for compounds that possess no antiviral activity on their own against SARS-CoV-2, such as the HCV NS5A inhibitor velpatasvir (29) . This suggests antiviral synergy may arise through direct inhibition of one or more viral factors as well as through modulation of host pathways. Further, as remdesivir is a direct inhibitor of the RdRP, the virus can be thought of as in a "weakened" or "sensitized" state in the presence of remdesivir, potentially making it more vulnerable to additional chemical compounds with no appreciable activity on their own. Taken together, the potential of combinatorial approaches, ideally against distinct molecular targets, holds promise and should be prioritized for in vivo studies to determine efficacy.

At the beginning of the COVID-19 pandemic, many groups utilized a variety of genetic, proteomic, and chemical screening strategies to identify potential drugs for repurposing against SARS-CoV-2. These studies differ in the cell type selected for screening and in the assays used to determine viral replication. Most SARS-CoV-2 drug screens to date have utilized either an IFA-based approach or a CPE-based approach. In general, the IFA-based screens investigate antiviral activity earlier than CPE-based studies (typically 1-2 dpi vs. 3-4 dpi respectively) adding a selection bias for compounds that are effective at early time-points, as many compounds with mild antiviral activity (or shorter half-lives) may be overcome by viral replication at later time points. In addition to the need to interpret in vitro assay data carefully, our study highlights the importance of cell type selection when screening for antiviral compounds in vitro. Use of multiple cell lines is critical. In particular, many early studies used Vero cells due to their widespread availability, permissiveness to SARS-CoV-2 infection, and ease of use and manipulation.

However, we found that activity of compounds against SARS-CoV-2 in Vero cells does not correlate well with activity in Calu-3 cells, an arguably more relevant human epithelial cell line.

Thus, when interpreting in vitro antiviral candidates, both cell type, readout, and relative timing of drug and virus addition need to be carefully considered.

Although several COVID-19 vaccines have received Emergency Use Authorization recently by the FDA, pharmaceutical therapies for COVID-19 patients will continue to be urgently needed.

Vaccines will not be widely available for several months, however more importantly, even an optimal vaccine will not eliminate severe COVID-19 due to limitations of vaccine use and efficacy in specific populations such as immunocompromised and pediatric patients. Our study identified 7 compounds not previously demonstrated to have antiviral activity with potential for COVID-19 therapy, one of them strongly synergistic with the approved COVID-19 therapeutic remdesivir. Intriguingly, budesonide is already studied in clinical trials for COVID-19 treatment because of its anti-inflammatory properties, and if positive, antiviral efficacy should be considered as an additional pharmacodynamic effect. Investigation into the mechanism of action and in vivo efficacy of these compounds is of paramount importance, as is defining the safety profiles of these compounds alone and in combination with remdesivir in humans. Such studies are currently underway in our lab as well as in other labs, but further collaboration is needed to expedite this process and provide access to pre-clinical and clinical testing to alleviate the global COVID-19 pandemic.

Multiple cell lines were acquired in this study to determine permissiveness to SARS-CoV-2 for use in drug screens. Vero-E6 cells were acquired from the American Type Culture Collection 

The USA-WA1/2020 strain of SARS-CoV-2 was obtained from BEI Resources. The initial stock from BEI was passed through a 0.45 µM syringe filter and 5 µl of this filtered stock was inoculated onto ~80% confluent T175 flasks (Nunc, Roskilde, Denmark) of Vero-E6 cells to produce passage 1 of the virus. CPE was monitored daily and flasks were frozen down when cells exhibited 50-70% cytopathic effect (CPE) (48-72 hpi). Thawed lysates were then collected and cell debris was pelleted at 3000 x rpm for 20 minutes. Clarified viral supernatant was then aliquoted and infectious virus was quantified via a TCID50 assay. To produce passage 2 SARS-CoV-2 working stocks, 5 µl of the passage 1 stock was inoculated onto ~80% confluent T175 flasks of Vero-E6 cells as described above. Viral titers produced in Vero-E6 cells ranged from 1x10 6 -5x10 6 TCID50 units / mL.

The compound screening and 384-well infection experiments were conducted as described previously (29) and are described below. The FDA-approved drug library (Targetmol) and the Statistical significance between experimental conditions were assessed using a two-tailed, heteroscedastic student's t-test. Measurements were taken from distinct samples unless indicated otherwise. The data was plotted and analyzed with Spotfire (Tibco) and GraphPad Prism (San Diego, CA).

The methods for GSEA analysis conducted for this study were previously reported and described below (29) . In brief, candidate compounds identified in our screens were assigned distinct properties based on known host targets and pathways using the Center for Emerging and Neglected Diseases' database and for pharmacokinetic data and transporter inhibition data, the DrugBank database. Each assigned property was tested for enrichment among the screening hits using the gene set enrichment analysis (GSEA) software as described (22, 56, 57) . Compounds annotated for each property were considered as part of the "gene set". For each set of annotations, the background compound set was defined as the set of compounds annotated for any property. GSEA preranked analysis was performed using the compounds' % CPE inhibition from each screen. Compound sets included in the analysis were between 5 and 500 compounds. The enrichment score (ES) reflects the degree to which a gene set is overrepresented at the top of a ranked list of compounds interacting with the given target. GSEA calculates the ES by walking down the ranked list of compounds interacting with the given target, increasing a running-sum statistic when a gene is in the gene set and decreasing it when it is not. TCID50 assay 5x10 4 Calu-3 cells were seeded into 96-well plates 48 hours before adding drug combinations and viral inoculum (MOI 0.05) (viral inoculum was not washed away). At 24 hpi supernatant was collected from each well and serially diluted, and each dilution was applied to eight wells in 96well plates containing Vero-E6 cells. Three days later, CPE was counted visually and TCID50/mL was calculated using the dilution factor required to produce CPE in half, or 4/8, of the wells for a given dilution.

RT-qPCR was conducted as previously reported (29) reactions. RT-qPCR was performed on a BioRad CFX96 or CFX384 instrument with the following cycle: 1) 25°C for 1min, 2) 50°C for 15min, 3) 95°C for 2min, 4) 95°C for 3s, 5) 55°C for 30s (read fluorescence), 6) go to step 4 for 44 repetitions. Quantification cycle (Cq) values were determined using the second derivative peak method (58) . Custom code written in MATLAB (available at https://gitlab.com/tjian-darzacq-lab/second-derivative-cq-analysis) was used to take the numerical second derivative of fluorescence intensity with respect to cycle number, using a sliding window of ± 3 cycles. The peak of the second derivative was fit to a parabola, whose center was taken to be the Cq value (58) .

Compounds were dissolved in DMSO at 50X the desired screening concentration. DMSO was used as a solvent control. MPro protein (purification described below) was diluted in assay 

The coding sequence for SARS-CoV-2 main protease was codon-optimized for E. coli and synthesized by Integrated DNA Technologies. The sequence was amplified by PCR and cloned into the pGEX6P-1 vector, downstream of GST and an HRV 3C protease cleavage site, using the Gibson Assembly Master Mix kit (New England BioLabs, Inc). To ensure authentic termini, the amino acids AVLQ were added to the N-terminus of the main protease by addition of their coding sequence to the 5′ end of the gene product. This sequence reconstitutes the SARS-CoV-2 NSP4/5 cleavage site, resulting in auto-cleavage by the main protease protein product (59) .

Similarly, we added a GP-6xHis tag for IMAC purification to the C-terminus (the GP completes a non-consensus 3C cleavage site along with the C-terminus of the main protease which allows for cleavage of the his tag after purification, resulting in an authentic C-terminus).

Hi Control BL21(DE3) cells were transformed with the expression plasmid using standard techniques. We used Hi Control cells as we observed expression of the main protease was toxic in other standard E. coli cell lines. A single colony was used to start an overnight culture in LB + carbenicillin media. This culture was used to inoculate 2 x 1 L cultures in Terrific Broth, Pooled fractions were treated with HRV 3C protease (also known as "PreScission" protease) while dialyzing against IMAC_A buffer at room temperature (2 x 2 L dialyses). Room temperature dialysis was important as we observed a tendency for the main protease protein to precipitate with prolonged exposure to 4 °C. Cleavage of the C-terminal GP-6xHis tag was confirmed after 2 hours by ESI-LC/MS. The dialyzed and cleaved protein was then re-run through a 5 mL HiTrap Ni-NTA column pre-equilibrated with IMAC_A buffer. The main protease eluted in the flow-through as expected.

The protein was then concentrated to approximately 5 mL and loaded onto a Superdex 75 16/60 column pre-equilibrated with SEC Buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP). The protein was run through the column at 1 mL/min and eluted as one large peak well in the included volume (at ~75 mL). Fractions from this peak were analyzed by SDS-PAGE and pure fractions were pooled and concentrated to 10 mg/mL, aliquoted, and stored at -80 °C. Final yield was typically in the realm of 60-70 mg/L of culture.

Compounds were dissolved in DMSO at 50X the desired screening concentration. DMSO was used as a solvent control. PLpro protein was purified as described below. The screening assay was performed in black 384 well plates (Corning 384-Well, Flat-Bottom Microplate), and was performed in a 25.5 µL volume which contained a final PLpro concentration of 50 nM, a 50 µM concentration of substrate (RLRGG-AMC), and 0.5µl of DMSO or compound (final concentration of 40µM), the final assay buffer contained 20mM Hepes pH 7.5, 100mM NaCl and 0.1% mg/ml BSA. Screens were performed with 1:5000 antifoam to reduce the surface tension and bubbles.

After addition of the substrate, the RFU value was measured on a Tecan Spark plate reader with an excitation wavelength of 360 nm and an emission wavelength of 460 nm at 30 °C for 30 min.

The papain-like protease (PLpro) expressing plasmid, 2BT-Nsp3-PLpro was transformed into E. coli BL21 (DE3) and plated on ampicillin resistant LB agar plate. The next day, a colony was picked up for overnight culture in the presence of ampicillin 100µg/ml. For large-scale protein purification, a 1L culture of 2XYT media was grown using overnight culture (1:100) at 37°C (210 rpm). The bacterial culture was grown to an OD600 ~0.8-1.0 and induced with 1mM IPTG. The protein was expressed at 20°C for overnight (18-20 hours) . The bacterial culture was harvested at 4000 X g and cell pellets were resuspended in 30 mL lysis buffer (25mM Tris-HCl pH 8.0, 250mM NaCl, 10% glycerol, 5mM β-mercaptoethanol), supplemented with protease inhibitor tablets. The cell culture was sonicated at 20% amplitude for 7 minutes (0.5 sec ON, 1.5 sec OFF). 

Human viruses: discovery and emergence

The consequences of human actions on risks for infectious diseases: a review

The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century

Coronavirus Infections-More Than Just the Common Cold

The molecular virology of Coronaviruses

Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Clinical Characteristics of Coronavirus Disease 2019 in China

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Clinical characteristics of 82 cases of death from COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Remdesivir for the Treatment of Covid-19 -Final Report

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2. bioRxiv

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv

Generation of human pulmonary microvascular endothelial cell lines

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL

Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. bioRxiv

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Current Perspective of Antiviral Strategies against COVID-19

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19. bioRxiv

Repurposing old drugs as antiviral agents for coronaviruses

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate. bioRxiv

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection

Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells

Glycogen synthase kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus nucleocapsid protein and viral replication

SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2. bioRxiv

Phosphoregulation of Rad51/Rad52 by CDK1 functions as a molecular switch for cell cycle-specific activation of homologous recombination

Role of the human RAD51 protein in homologous recombination and double-stranded-break repair

Breaking Bad: How Viruses Subvert the Cell Cycle

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase

Rad51 Interacts with Non-structural 3 Protein of Hepatitis C Virus and Regulates Viral Production

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

Real-time multiplex PCR assays

Production of authentic SARS-CoV M(pro) with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction

We thank Dr. Ella Hartenian (UC Berkeley) and Dr. Britt Glaunsinger (UC Berkeley) for assistance with cloning the human ACE2 gene into a lentivirus construct. We thank Dr. Patrick S. Mitchell We further thank members of the Harris and Stanley labs for helpful discussion. We would like to acknowledge receipt of diverse cell lines used in this study from the UCB Cell Culture facility, which is supported by the University of California, Berkeley. SARS-CoV-2 clinical isolate USA-WA1/2020, NR-52281 was obtained through BEI resources, NIAID, NIH and deposited by the